Merck & Co., Inc. (MRK)
MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer
The FDA grants priority review to Merck and Daiichi's BLA for ifinatamab deruxtecan to treat extensive-stage small cell lung cancer.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Merck (MRK) closed at $120.15, marking a -1.05% move from the previous day.
1Q26 Earnings: Where Street Estimates Are Too Low & Who Should Beat
GAAP earnings, despite popular opinion, don't accurately measure profits. Companies can, and do, manipulate GAAP earnings through accounting rule loopholes.
Merck (MRK) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Merck (MRK) settling at $119.28, representing a -1.3% change from its previous close.
Merck Just Made a Big Bet on a New Cancer Growth Engine
The drugmaker's stock recently got a shot in the arm on the news of it acquiring Terns Pharmaceutical—a move that will not only bolster its cancer treatment pipeline but also reinforce Merck's role as a top-tier serial acquirer.
Infinimmune, Merck enter into antibody discovery pact
Biotech firm Infinimmune said on Tuesday it has entered into a deal with Merck , that could be worth up to about $838 million in milestone payments, to discover and develop multiple antibodies for various undisclosed disease targets.
Can MRK's Ongoing M&A Push Aid Long-Term Growth Ahead of Keytruda LOE?
Merck's recent M&A spree, including its $6.7B Terns deal, aims to diversify its pipeline and revenue base as Keytruda nears its 2028 exclusivity loss.
Merck Stock Soars 50% in 6 Months: Buy, Hold, or Take Profits?
MRK stock has surged over 50% in six months, but looming patent risks and weak vaccine sales raise questions on whether investors should hold or trim.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Merck & Co., Inc. (MRK) M&A Call Transcript
Merck & Co., Inc. (MRK) M&A Call Transcript
Merck makes a big move into new cancer treatments with a $6.7 billion buyout deal
Merck to spend $6.7 billion to buy Terns Pharmaceuticals, which is developing an oral treatment for leukemia.
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
